What is the main purpose of this 8-K filing?

The primary purpose of this 8-K filing is to formally announce and provide Abbott Laboratories' financial results for the first quarter of 2020, as detailed in the accompanying press release.

Why does Abbott use non-GAAP financial measures?

Abbott uses non-GAAP financial measures to provide investors with a clearer view of the company's ongoing operational performance by excluding unusual or unpredictable items. These adjustments include expenses related to acquisitions, restructuring, R&D assets, asset impairments, and specific tax benefits.

How should investors interpret the non-GAAP measures?

Investors should interpret these non-GAAP measures as a supplementary view of performance, as intended by management. However, it is crucial to consider these figures alongside, and not as a replacement for, the company's financial results prepared in accordance with Generally Accepted Accounting Principles (GAAP).

What key financial details are provided in the press release?

While the 8-K filing itself does not contain the detailed financial tables, it incorporates by reference a press release (Exhibit 99.1) which would contain the specific Q1 2020 financial results, including net earnings and other performance metrics, both on a GAAP and non-GAAP basis.

ABT 8-K: Earnings & Results

Summary

Abbott Laboratories (ABT) filed an 8-K on April 16, 2020, to report its first-quarter 2020 financial results. The filing includes a press release detailing these results and specifies the use of non-GAAP financial measures. These non-GAAP measures adjust for significant items such as acquisition and restructuring expenses, R&D asset acquisition costs, asset impairments, and tax-related adjustments, offering a view of ongoing operational performance as assessed by management. Investors should note that while Abbott's management believes these non-GAAP figures provide valuable insights into operational performance, they should be considered alongside, and not as a substitute for, GAAP-based financial measures. The report primarily serves to furnish the Q1 2020 earnings release, highlighting the company's financial performance during a period that would soon be significantly impacted by global events.

Key Highlights

1Abbott Laboratories announced its first-quarter 2020 financial results on April 16, 2020, via an 8-K filing.
2The filing includes a furnished press release (Exhibit 99.1) detailing the Q1 2020 earnings.
3Abbott utilizes non-GAAP financial measures to present results, excluding items like acquisition and restructuring costs, R&D asset charges, asset impairments, and certain tax benefits.
4Management believes these non-GAAP measures offer greater visibility into ongoing business performance.
5Investors are advised to consider these non-GAAP measures in conjunction with GAAP financial measures.
6The report confirms the CFO, Robert E. Funck, Jr., signed the filing.
7This filing occurred just as the significant economic impacts of the COVID-19 pandemic were beginning to be felt globally.

ABBOTT LABORATORIES 8-K Report, Financial Results (Apr 16, 2020)

Summary

Key Highlights

Frequently Asked Questions